[1] 徐爱华.替诺福韦酯治疗妊娠慢性乙肝患者的疗效及母婴阻断效果研究.中国社区医师,2017,33:35-37. [2] Andersson MI,Rajbhandari R,Kew MC,et al.Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa:time to act.Lancet Glob Health,2015,3:e358-359. [3] 吴晓莉,江建宁,苏明华,等.核苷(酸) 类似物阻断HBV 母婴传播的效果及安全性.山东医药,2015,55: 21-23. [4] 白淑芬,杨立新,韩国荣.母亲HBsAg 阳性与所生新生儿HBsAg 阳性相关性分析.中华实用诊断与治疗杂志,2014,28:724-725. [5] Kang W,Ding Z,Shen L,et al.Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in of hepatitis B virus and he Yunnan province,China.Vaccine, 2014, 32:3362-3366. [6] Wang AL,Qiao YP,Wang LH,et al.Integrated prevention of mother-to-child transmission for human immunodeficiency virus,syphilis and hepatitis B virus in China.Bull World Health Organ,2015,93:52-56. [7] Pan CQ,Duan Z, Dai E,et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med,2016,374:2324-2334. [8] 齐丽韫,赵志军,刘加群.替诺福韦酯治疗妊娠慢性乙肝患者的疗效及母婴阻断的有效性研究.中国医药导刊,2017,19:176-177. |